Q3 2026 Senores Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Senores Pharmaceuticals Ltd (NSE:SENORES) reported a strong performance with a 64% year-over-year growth in consolidated income for Q3 FY26.
- The company achieved a 60% growth in revenue from regulated markets, driven by product portfolio expansion and strategic sales channels.
- The acquisition of a 75% stake in Apnar Pharma, with its US FDA approved facility, is expected to enhance manufacturing capabilities and provide strategic benefits.
- The emerging market business showed significant improvement, achieving its highest ever quarterly revenue, EBITDA, and PAT, and is now cash flow positive.
- The company has a robust pipeline with 28 approved ANDAs ready for launch and 22 more molecules under development, ensuring sustained growth.
- The contribution from Apnar Pharma is still uncertain in terms of margin expansion, as the facility is yet to reach optimal utilization.
- The company's API segment remains a small contributor, primarily focused on strategic backward integration rather than revenue generation.
- There is a significant difference in gross margins between own products and CDMO/CMO business, with CDMO/CMO margins being lower.
- The company has not provided specific guidance on the expected margin expansion from the Apnar acquisition.
- Despite strong growth, the company remains conservative in revising its FY26 top-line guidance, sticking to a 50% growth target.
Ladies and gentlemen, good day and welcome to Senores Pharmaceuticals Limited Q3 FY26 results call hosted by Ambit Capital Private Limited. (Operator Instructions) Please note that this conference is being recorded.
And now I hand the conference or to Mr. Gaurav Tinani from Ambit Capital Private Limited. Thank you and over to you, sir.
Thank you. Good evening everyone. On behalf of Ambit Capital. I would like to welcome you all to the Q3 FY26 earnings call for Senores Pharmaceuticals Limited. Joining us from the management today, we have Mr. Swapnil Shah, the Managing Director; Mr. Sanjay Majmudar, the Chairman; and Mr. Deval Shah, the Chief Financial Officer.
I thank the management for the opportunity to host this earnings call. Before we begin, I would like to point out that this conference call may contain some forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on the date of this call.
These statements are not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
